Dr. Ray H. Clark

Rajen Mody is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Mody is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, Neuroepithelioma, and Bone Marrow Aspiration. Dr. Mody is currently accepting new patients.

The T-cell lymphomas are a heterogeneous and poorly understood group of non-Hodgkin’s lymphomas. The most common T-cell lymphoma in the United States includes a heterogeneous mix of lymphomas that lack distinguishing characteristics and, until recently, remained clinically and molecularly “unspecified”. Improved understanding of T-cell lymphoma pathogenesis and the development of novel therapeutic strategies will be needed to address this challenge and improve outcomes for patients afflicted with these aggressive lymphomas. My group made the landmark discovery that the most common T-cell lymphoma in North America is comprised of two molecularly and clinically distinct subsets. This finding has significant implications for the classification and treatment of these lymphomas. We have also demonstrated that malignant T cells remain dependent upon antigen-presenting cells within the tumor microenvironment and are developing novel therapeutic strategies targeting these cells. Many fundamental questions, including the “cell of origin”, the role of antigen-, costimulatory-, and cytokine-receptor signaling, and the contribution of myeloid-derived antigen-presenting cells in disease pathogenesis remain obscure. My laboratory uses complementary mouse models and primary T-cell lymphoma specimens (in ex vivo and patient-derived xenograft studies) to address these fundamental and clinically relevant questions. We are poised to clinically translate our laboratory-based findings into novel therapeutic strategies that we hope will improve outcomes for patients afflicted with these aggressive lymphomas. I enjoy working with a multidisciplinary team of enthusiastic collaborators who share this common goal. Dr. Wilcox is highly rated in 23 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Wilcox is board certified in Hematology, Internal Medicine, and Medical Oncology. Dr. Wilcox is currently accepting new patients.

Dr. Dale Bixby has been practicing hematology at the University of Michigan since 2009. He obtained his PhD in Medicinal Chemistry and Pharmaceutics at the University of Kentucky in 1999, before beginning his medical training at the University of Michigan in Ann Arbor, MI. He was a resident in the Department of Internal Medicine and then completed fellowship training in hematology and medical oncology at the University of Michigan. Dr. Bixby is currently a clinical professor and specializes in the areas of myeloid and lymphoid leukemias, myelodysplastic syndrome and bone marrow failure disorders. Dr. Bixby currently serves as the section chief of the acute leukemia program. He is also a clinical investigator in hematological malignancies. Dr. Bixby is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), and Bone Marrow Aspiration. Dr. Bixby is board certified in Hematology. Dr. Bixby is currently accepting new patients.